- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

July 29, 2010 — The US Food and Drug Administration (FDA) has approved glycopyrrolate oral solution (Cuvposa; Shionogi Pharma, Inc) for the treatment of patients aged 3 to 16 years with chronic severe ...

Sciele Pharma announced that it has submitted a New Drug Application (NDA) to the FDA for glycopyrrolate oral solution to treat chronic, moderate-to-severe drooling in pediatric patients. This ...

On August 20, Granules India announced that its subsidiary, Granules Pharmaceuticals Inc, has received approval from the US Food and Drug Administration (USFDA) for a generic version of Glycopyrrolate ...

GREENSBORO, N.C., Aug. 27, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the acquisition of CUVPOSA ® (glycopyrrolate) oral solution for pediatric chronic ...

DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP ) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic ...

FLORHAM PARK, N.J., April 7, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial ...

Granules India announced that its subsidiary, Granules Pharmaceuticals Inc, has received approval from the US FDA for a generic version of Glycopyrrolate Oral Solution, 1 mg/5 mL. This anticholinergic ...

Drugmaker Granules India on August 20 said its arm Granules Pharmaceuticals Inc has received approval from the US health regulator for a generic Glycopyrrolate oral solution, indicated for pediatric ...